Journal articleNat Commun2024
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
- Journal
- Nat Commun
- Published
- 20 March 2024
- Citations
- 33
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Grants 9
- Core A: Administrative Core P50CA272213↗
- Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy R01CA244938↗
- Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity R01CA248917↗
- Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer R01CA262414↗
- Re-wiring PDAC Tumor Immunity Through Dendritic Cells R01CA262506↗
- Stomal Senescence Regulator of Tumor Immunity and Progression R01CA286615↗
- IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA R37CA219697↗
- The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity U01CA284086↗
- Research Project 2 U54CA224083↗